SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs(India) - Quaterly Results

19 May 2025 Evaluate
The sales figure stood at Rs. 563.04 millions for the March 2025 quarter. The mentioned figure indicates a growth of about 43.87% as compared to Rs. 391.36 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 212.27% to Rs. 113.73  millions  from Rs. 36.42 millions in previous same quarter.OP of the company witnessed a marginal growth to 162.30 millions from 61.13 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 563.04 391.36 43.87 1815.87 1315.99 37.99 1815.87 1315.99 37.99
Other Income 23.25 8.96 159.49 137.15 61.89 121.60 137.15 61.89 121.60
PBIDT 162.30 61.13 165.50 445.53 265.06 68.09 445.53 265.06 68.09
Interest 7.21 4.45 62.02 21.26 19.08 11.43 21.26 19.08 11.43
PBDT 155.09 56.68 173.62 424.27 245.98 72.48 424.27 245.98 72.48
Depreciation 5.11 4.10 24.63 17.37 12.44 39.63 17.37 12.44 39.63
PBT 149.98 52.58 185.24 406.90 233.54 74.23 406.90 233.54 74.23
TAX 36.25 16.16 124.32 95.33 57.79 64.96 95.33 57.79 64.96
Deferred Tax 0.66 3.01 -78.07 -3.17 -5.86 -45.90 -3.17 -5.86 -45.90
PAT 113.73 36.42 212.27 311.57 175.75 77.28 311.57 175.75 77.28
Equity 160.82 160.82 0.00 160.82 160.82 0.00 160.82 160.82 0.00
PBIDTM(%) 28.83 15.62 84.54 24.54 20.14 21.82 24.54 20.14 21.82

Kilitch Drugs(India) Share Price

154.85 2.85 (1.88%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×